Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
Dengue is one of the neglected tropical diseases caused by flavivirus. Live-attenuated tetravalent vaccine is launched for the age group of 9–45 years. It is given in three doses schedule. Eleven studies were included in meta-analysis by following PRISMA guidelines. Healthy persons in the age group...
Main Authors: | Ashish Wasudeo Khobragade, Dilip D Kadam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Community Medicine |
Subjects: | |
Online Access: | http://www.ijcm.org.in/article.asp?issn=0970-0218;year=2021;volume=46;issue=2;spage=191;epage=194;aulast= |
Similar Items
-
Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020-10-01) -
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01) -
Clinical development update: 1st dengue vaccine candidate
by: Alain Bouckenooghe
Published: (2016-02-01) -
Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
by: Kirill Nemirov, et al.
Published: (2023-08-01) -
Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
by: Guy El Helou, et al.
Published: (2020-06-01)